Why the study?
Does valsartan reduce systolic and diastolic blood pressure in children aged 1 to 5 years with hypertension?
Does valsartan reduce systolic and diastolic blood pressure in children aged 1 to 5 years with hypertension?
Valsartan effectively and safely lowers systolic and diastolic blood pressure in hypertensive children under 6 years of age without negatively affecting growth and development.
Answers are grounded in this paper and cite their sources.
Supports valsartan for BP lowering in children aged 1-5; extends RCT evidence to this previously understudied group.
The efficacy and safety of valsartan were studied in 90 children (mean age: 3.2 years; 60% male; 30% black) with systolic blood pressure (SBP) > or =95th percentile. Nineteen percent received valsartan in addition to previous antihypertensive therapy. Subjects were randomly assigned to low-, medium-, or high-dose valsartan for 2 weeks (phase 1) and then reassigned randomly to placebo or to remain on the same valsartan dose for 2 additional weeks (phase 2). After this, subjects were enrolled into a 52-week, open-label phase during which valsartan was dosed to achieve SBP <95th percentile. Statistically significant reductions in SBP and diastolic blood pressure of approximately 8.5 mm Hg and 5.7 mm Hg, respectively, were observed at the end of phase 1 in all of the valsartan dose groups. SBP and diastolic blood pressure were also significantly lower during phase 2 in valsartan recipients compared with placebo recipients. SBP <95th percentile was achieved in 77.3% of subjects during the open-label phase. Adverse events were minor and occurred at similar frequencies in each of the 3 dose groups in phase 1 and at equal frequencies in the valsartan and placebo arms in phase 2. Serious adverse events and drug-related adverse events occurred infrequently during both the double-blind (2.2% and 5.6%, respectively) and open-label (14.8% and 6.8%, respectively) portions of the study. Valsartan treatment had no demonstrable negative effects on growth and development. In this study, the first trial of an antihypertensive agent conducted in children <6 years of age, valsartan effectively lowered SBP and diastolic blood pressure compared with placebo.
No takes yet. Share an insight, caveat, or question.
Flynn et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: